TTRNA-xALT

Phase 2Biologic

UUniversity of Florida

TTRNA-xALT is one of 95 biologic programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

OligodendrogliomaActive, not recruiting

MedulloblastomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

Primitive Neuroectodermal TumorPhase 2

Active, not recruiting

OligodendrogliomaPhase 1

Active, not recruiting

MedulloblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Phase 3

2 2

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 3

Vepesid

AAvyxa

Phase 3

4 4

Ifex

BBaxter Healthcare Corporation

Phase 3

1 5

Rayos

RRoxane Laboratories

Phase 3

1 6

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 7

Velban

EEastern Cooperative Oncology Group

Phase 3

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 9

Modeyso

CChimerix

Phase 3

3 10

Chemotherapeutic Agent

Day One Biopharmaceuticals

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

Oligodendroglioma

NCT06254326

Q4 2028

Phase 1Active, not recruiting

Medulloblastoma

NCT06514898

Clinical

Trials by Indication[1]

Glioma2 trials

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas

Terminated·UUniversity of Florida·Phase 1·NCT03334305·18 enrolled

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Terminated·UUniversity of Florida·Phase 1·NCT03396575·11 enrolled

Oligodendroglioma1 trial

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

Active, not recruiting·UUniversity of Florida·Phase 1·NCT06254326·12 enrolled

Primitive Neuroectodermal Tumor1 trial

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

Completed·UUniversity of Florida·Phase 2·NCT01326104·26 enrolled

Medulloblastoma1 trial

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

Active, not recruiting·UUniversity of Florida·Phase 1·NCT06514898·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for TTRNA-xALT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TTRNA-xALT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TTRNA-xALT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Florida

TTRNA-xALT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Glioma2 trials

Oligodendroglioma1 trial

Primitive Neuroectodermal Tumor1 trial

Medulloblastoma1 trial

References

Drug Info

Quick Facts

Related News